Dr. Sotomayor on the Durability of CAR T Cells in Hematologic Malignancies

Video

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses the durability of CAR T cells, as well as ways to combat immune escape mechanisms in hematologic malignancies.

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses the durability of CAR T cells, as well as ways to combat immune escape mechanisms in hematologic malignancies.

CAR T cells can potentially persist for months or years, Sotomayor says. Moreover, the patient’s natural immune response can generate memory cells that attack recurrent cancer cells and allow continued clinical remission.

This is contingent on whether the cancer cells continue to express the molecule targeted by the CAR T cells like CD19 for example, or if they develop a mechanism of escape to avoid targeting and continue proliferation, Sotomayor says.

However, he adds, treatment is evolving to combat these mechanisms of escape by targeting multiple antigens such as CD20 or CD22. Due to tumor heterogeneity, this appears to be a lucrative strategy. Currently, there are ongoing clinical trials exploring this idea.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.